Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera

Raveen Rathnasinghe, Sonia Jangra, Anastasija Cupic, Carles Martínez-Romero, Lubbertus C.F. Mulder, Thomas Kehrer, Soner Yildiz, Angela Choi, Ignacio Mena, Jana De Vrieze, Sadaf Aslam, Daniel Stadlbauer, David A. Meekins, Chester D. McDowell, Velmurugan Balaraman, Juergen A. Richt, Bruno G. De Geest, Lisa Miorin, PVI study group, Florian Krammer, Viviana Simon, Adolfo García-Sastre, Michael Schotsaert
doi: https://doi.org/10.1101/2021.01.19.21249592
Raveen Rathnasinghe
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Jangra
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasija Cupic
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carles Martínez-Romero
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lubbertus C.F. Mulder
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Kehrer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soner Yildiz
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Choi
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio Mena
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana De Vrieze
4Department of Pharmaceutics, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sadaf Aslam
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Stadlbauer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Meekins
5Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chester D. McDowell
5Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Velmurugan Balaraman
5Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen A. Richt
5Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno G. De Geest
4Department of Pharmaceutics, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Miorin
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
Florian Krammer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviana Simon
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
6Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adolfo García-Sastre
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
6Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai New York, NY, USA
7The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.schotsaert@mssm.edu
Michael Schotsaert
1Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA
3Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.schotsaert@mssm.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The current COVID-19 (coronavirus disease 19) pandemic, caused by SARS-CoV-2, disproportionally affects the elderly and people with comorbidities like obesity and associated type 2 diabetes mellitus. Small animal models are crucial for the successful development and validation of antiviral vaccines, therapies and to study the role that comorbidities have on the outcome of viral infections. The initially available SARS-CoV-2 isolates require adaptation in order to use the mouse angiotensin converting enzyme 2 (mACE-2) entry receptor and to productively infect the cells of the murine respiratory tract. We have “mouse-adapted” SARS-CoV-2 by serial passaging a clinical virus isolate in the lungs of mice. We then used low doses of this virus in mouse models for advanced age, diabetes and obesity. Similar to SARS-CoV-2 infection in humans, the outcome of infection with mouse-adapted SARS-CoV-2 resulted in enhanced morbidity in aged and diabetic obese mice. Mutations associated with mouse adaptation occurred in the S, M, N and ORF8 genes. Interestingly, one mutation in the receptor binding domain of the S protein results in the change of an asparagine to tyrosine residue at position 501 (N501Y). This mutation is also present in the newly emerging SARS-CoV-2 variant viruses reported in the U.K. (20B/501Y.V1, B1.1.7 lineage) that is epidemiologically associated with high human to human transmission. We show that human convalescent and post vaccination sera can neutralize the newly emerging N501Y virus variant with similar efficiency as that of the reference USA-WA1/2020 virus, suggesting that current SARS-CoV-2 vaccines will protect against the 20B/501Y.V1 strain.

Competing Interest Statement

The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, ImmunityBio and Nanocomposix. Dr. Adolfo Garcia-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius and Esperovax. Mount Sinai has licensed SARS-CoV-2 serological assays to commercial entities and has filed for patent protection for serological assays as well as SARS-CoV-2 vaccines. F.K. is listed as inventors on the pending patent applications. The F.K. laboratory has received research support from GSK, Dynavax and Pfizer. F.K. has in the past received consulting fees from Curevac, Merck, Pfizer and Seqirus. A provisional patent application on a --A novel 4 Amino Acid Insertion into the Spike Protein of SARS-CoV-2-- was submitted by KSU in July 2020 with C.D.M., D.A.M and J.A.R listed as inventors.

Clinical Trial

NA

Funding Statement

This work was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (to A.G.-S., F.K. and V.S.) and contract HHSN 272201400006C (to J.A.R.), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (to A.G.-S., F.K. and V.S.), and the generous support of the JPB foundation (to A.G.-S., F.K. and V.S.), the Open Philanthropy Project (#2020-215611) (to A.G.-S., F.K., V.S.) and other philanthropic donations. This research was partly funded by NIH AI150355 grant to LCFM, by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), by the Defense Advanced Research Projects Agency (HR0011-19-2-0020), by supplements to NIAID grant U19AI135972 and DoD grant W81XWH-20-1-0270, by NCI grant U54CA260560, by a Mercatus Center Fast Grant, by the generous support of JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384); by anonymous donors to A.G.-S.. Funding for this study was provided through grants from the National Bio and Agro-Defense Facility (NBAF) Transition Funds from the State of Kansas, and DHS CEEZAD (HSHQDC16-A-B0006) to J.A.R. B.G.D.G acknowledges funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation program (grant N 817938). S.Y. is supported by The Swiss National Science Foundation (Early Postdoc Mobility Grant Project Id: P2GEP3_184202).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocols for the collection of clinical specimens from individuals with and without SARS-CoV-2 infection by the Personalized Virology Initiative were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-16-00791; IRB-20-03374). All participants provided informed consent prior to collection of specimen and clinical information. All specimens were coded prior to processing.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
Raveen Rathnasinghe, Sonia Jangra, Anastasija Cupic, Carles Martínez-Romero, Lubbertus C.F. Mulder, Thomas Kehrer, Soner Yildiz, Angela Choi, Ignacio Mena, Jana De Vrieze, Sadaf Aslam, Daniel Stadlbauer, David A. Meekins, Chester D. McDowell, Velmurugan Balaraman, Juergen A. Richt, Bruno G. De Geest, Lisa Miorin, PVI study group, Florian Krammer, Viviana Simon, Adolfo García-Sastre, Michael Schotsaert
medRxiv 2021.01.19.21249592; doi: https://doi.org/10.1101/2021.01.19.21249592
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
Raveen Rathnasinghe, Sonia Jangra, Anastasija Cupic, Carles Martínez-Romero, Lubbertus C.F. Mulder, Thomas Kehrer, Soner Yildiz, Angela Choi, Ignacio Mena, Jana De Vrieze, Sadaf Aslam, Daniel Stadlbauer, David A. Meekins, Chester D. McDowell, Velmurugan Balaraman, Juergen A. Richt, Bruno G. De Geest, Lisa Miorin, PVI study group, Florian Krammer, Viviana Simon, Adolfo García-Sastre, Michael Schotsaert
medRxiv 2021.01.19.21249592; doi: https://doi.org/10.1101/2021.01.19.21249592

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (450)
  • Dentistry and Oral Medicine (82)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5243)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (755)
  • Geriatric Medicine (80)
  • Health Economics (212)
  • Health Informatics (696)
  • Health Policy (356)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5846)
  • Intensive Care and Critical Care Medicine (358)
  • Medical Education (103)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (762)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (476)
  • Ophthalmology (150)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (140)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (858)
  • Public and Global Health (2003)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (94)
  • Sexual and Reproductive Health (73)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)